



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07D 215/36, A61K 31/47		A1	(11) International Publication Number: WO 91/02724
			(43) International Publication Date: 7 March 1991 (07.03.91)
(21) International Application Number: PCT/EP90/01376 (22) International Filing Date: 17 August 1990 (17.08.90) (30) Priority data: 8918952.6 19 August 1989 (19.08.89) GB (71) Applicant (for all designated States except US): THE BOOTS COMPANY PLC [GB/GB]; 1 Thane Road West, Nottingham NG2 3AA (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): DAVIES, Roy, Victor [GB/GB]; 108 Ashland Road West, Sutton-In-Ashfield, Nottinghamshire NG17 2HS (GB). ROBINSON, Keith [GB/GB]; 46 Thorneywood Mount, Thorneywood, Nottingham NG3 2PZ (GB).		(74) Agent: THACKER, Michael, Anthony; The Boots Company plc, Patents Department, R4 Pennyfoot Street, Nottingham NG2 3AA (GB). (81) Designated States: AT (European patent), AU, BE (European patent), BG, BR, CA, CH (European patent), DE (European patent)*, DK (European patent), ES (European patent), FI, FR (European patent), GB (European patent), HU, IT (European patent), JP, KR, LU (European patent), NL (European patent), NO, RO, SE (European patent), SU, US. Published With international search report.	
(54) Title: THERAPEUTIC AGENTS			
<div style="text-align: center;"> <p style="text-align: right;">(I)</p> </div>			
(57) Abstract			
<p>Compounds of formula (I), in which R¹ is lower alkyl; R² is lower alkyl; R³ is halogenated lower alkoxy, halogenated lower alkylthio, halogenated lower alkylsulphinyl or halogenated lower alkylsulphonyl; R⁴ and R⁵, which may be the same or different, are hydrogen, lower alkyl, lower alkoxy, lower alkylthio, lower alkylsulphinyl, lower alkylsulphonyl, halo, halogenated lower alkyl, halogenated lower alkoxy, halogenated lower alkylthio, halogenated lower alkylsulphinyl, halogenated lower alkylsulphonyl, cyano, phenyl or phenyl substituted by 1 to 3, especially 1 or 2, groups selected from lower alkyl, lower alkoxy, halo or halogenated lower alkyl; m is 0 or 1; and n is 0, 1 or 2, have antihypertensive activity. Processes for preparing compounds of formula (I) and pharmaceutical compositions containing them are described.</p>			

* See back of page

DESIGNATIONS DE "DE"

Jusqu'à nouvel avis, toute désignation de "DE" dans toute demande internationale dont la date de dépôt international est antérieure au 3 octobre 1990 a effet dans le territoire de la République fédérale d'Allemagne à l'exception du territoire de l'ancienne République démocratique allemande.

UNIQUEMENT A TITRE D'INFORMATION

Codes utilisés pour identifier les Etats parties au PCT, sur les pages de couverture des brochures publiant des demandes internationales en vertu du PCT.


AT	Autriche	ES	Espagne	MC	Monaco
AU	Australie	FI	Finlande	MG	Madagascar
BB	Barbade	FR	France	ML	Mali
BE	Belgique	GA	Gabon	MR	Mauritanie
BF	Burkina Faso	GB	Royaume-Uni	MW	Malawi
BG	Bulgarie	GR	Grèce	NL	Pays-Bas
BJ	Bénin	HU	Hongrie	NO	Norvège
BR	Brésil	IT	Italie	PL	Pologne
CA	Canada	JP	Japon	RO	Roumanie
CF	République Centrafricaine	KP	République populaire démocratique de Corée	SD	Soudan
CG	Congo	KR	République de Corée	SE	Suède
CH	Suisse	LI	Liechtenstein	SN	Sénégal
CM	Cameroun	LK	Sri Lanka	SU	Union soviétique
DE	Allemagne	LU	Luxembourg	TD	Tchad
DK	Danemark			TG	Togo
				US	Etats-Unis d'Amérique

- 1 -

THERAPEUTIC AGENTS

This invention relates to novel quinolones having therapeutic activity useful in treating cardiovascular diseases, therapeutic compositions containing the novel quinolones and to processes for preparing the novel quinolones.

The present invention provides quinolones of formula I



I

in which R^1 is lower alkyl; R^2 is lower alkyl; R^3 is halogenated lower alkoxy, halogenated lower alkylthio, halogenated lower alkylsulphanyl or halogenated lower alkylsulphonyl; R^4 and R^5 , which may be the same or different, are hydrogen, lower alkyl, lower alkoxy, lower alkylthio, lower alkylsulphanyl, lower alkylsulphonyl, halo, halogenated lower alkyl, halogenated lower alkoxy, halogenated lower alkylthio, halogenated lower alkylsulphanyl, halogenated lower alkylsulphonyl, cyano, phenyl or phenyl substituted by 1 to 3, especially 1 or 2, groups selected from lower alkyl, lower alkoxy, halo or halogenated lower alkyl; m is 0 or 1; and n is 0, 1 or 2.

The term "lower" as used herein signifies a group which may be straight or branched and which has 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms. Lower alkyl substituents include, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl and hexyl. Lower alkoxy

- 2 -

substituents include, for example, methoxy, ethoxy, propoxy, isopropoxy, butoxy and isobutoxy. Lower alkylthio substituents include, for example, methylthio, ethylthio, propylthio, isopropylthio, butylthio and isobutylthio.

The term "halo" signifies fluoro, chloro or bromo. Halogenated substituents include fluorinated and chlorinated, preferably fluorinated, substituents such as, for example, trifluoromethyl, trifluoromethoxy, difluoromethoxy, 2,2,2-trifluoroethoxy, trifluoromethylthio, trifluoromethylsulphinyl and trifluoromethylsulphonyl.


When at least one of R^4 and R^5 is substituted phenyl the substituents may be selected from lower alkyl such as methyl or ethyl, lower alkoxy such as methoxy or ethoxy, halo such as chloro or fluoro, and halogenated lower alkyl such as trifluoromethyl.

Specific compounds of formula I are:

- 1-methyl-3-methylthio-7-trifluoromethoxy-4-quinolone;
- 1-methyl-3-methylthio-7-trifluoromethylthio-4-quinolone;
- 1-methyl-3-methylsulphinyl-7-trifluoromethoxy-4-quinolone, including R and S forms thereof;
- 1-methyl-3-methylsulphinyl-7-trifluoromethylthio-4-quinolone, including R and S forms thereof;
- 1-methyl-3-methylsulphonyl-7-trifluoromethoxy-4-quinolone;
- 1-methyl-3-methylsulphonyl-7-trifluoromethylthio-4-quinolone;
- 7-difluoromethoxy-1-methyl-3-methylsulphinyl-4-quinolone, including R and S forms thereof; and
- 1-methyl-3-methylsulphinyl-7-(2,2,2-trifluoroethoxy)-4-quinolone, including R and S forms thereof.

- 3 -

A preferred group of compounds of formula I may be represented by formula II



II

in which R¹, R², R³ and n are as hereinbefore defined.

In preferred compounds of formula II, R¹ is alkyl
5 having 1 to 4 carbon atoms; R² is alkyl having 1 to 4
carbon atoms; R³ is fluorinated alkoxy having 1 to 4
carbon atoms, fluorinated alkylthio having 1 to 4
carbon atoms, fluorinated alkylsulphinyl having 1 to 4
carbon atoms or fluorinated alkylsulphonyl having 1 to
10 4 carbon atoms; and n is 0, 1 or 2.

More preferred compounds of formula II are those
in which R¹ is alkyl having 1 to 4 carbon atoms; R² is
alkyl having 1 to 4 carbon atoms; R³ is
trifluoromethoxy, 2,2,2-trifluoroethoxy, difluoro-
15 methoxy or trifluoromethylthio; and n is 0, 1 or 2.

In particularly preferred compounds of formula II,
R¹ and R² are methyl; R³ is trifluoromethoxy, 2,2,2-
trifluoroethoxy, difluoromethoxy or trifluoromethyl-
thio; and n is 0, 1 or 2.

20 Especially preferred compounds of formula II are
those in which R¹ and R² are methyl; R³ is trifluoro-
methoxy or trifluoromethylthio; and n is 0, 1 or 2,
preferably 0 or 1, most preferably 0.

Certain of the compounds of formula I may form
25 acid addition salts with certain acids. It will be

- 4 -

appreciated that such salts, provided they are pharmaceutically acceptable, may be used in therapy in place of the corresponding compounds of formula I. Such salts may be prepared for example by reacting the
5 compound of formula I with a suitable acid in a conventional manner.

It will also be appreciated by those skilled in the art that certain compounds of formula I contain one or more chiral centres. Thus, compounds of formula I
10 in which n is 1 contain a chiral centre at the sulphur atom and certain of the substituents R^1 , R^2 , R^3 , R^4 and R^5 also contain at least one chiral centre, for example when R^1 , R^2 , R^4 or R^5 is sec-butyl or R^3 , R^4 or R^5 is trifluoromethylsulphonyl. Such compounds may exist as
15 two or more stereochemical isomers. When a compound of formula I contains a single chiral centre it may exist in two enantiomeric forms which may be obtained by methods known to those skilled in the art. Such methods typically include resolution via formation of
20 diastereoisomeric salts or complexes which may be separated, for example, by crystallisation; formation of diastereoisomeric derivatives which may be separated, for example, by crystallisation, gas-liquid or liquid chromatography; selective derivatisation of
25 one enantiomer by reaction with an enantiomer-specific reagent, for example enzymatic oxidation or reduction; or gas-liquid or liquid chromatography in a chiral environment, for example on a chiral support or in the presence of a chiral solvent. Alternatively, it may be
30 possible to synthesise a specific enantiomer by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents, or to convert one enantiomer into the other by asymmetric transformation. The present invention includes each enantiomer of
35 compounds of formula I and mixtures thereof. When a compound of formula I contains more than one chiral

- 5 -

centre it may exist in diastereoisomeric forms. The diastereoisomers may be separated by methods known to those skilled in the art, for example chromatography or crystallisation. The present invention includes each
5 diastereoisomer of compounds of formula I and mixtures thereof.

Certain compounds of formula I may exist in more than one crystal form and the present invention includes each crystal form and mixtures thereof.

10 Certain compounds of formula I may also exist in the form of solvates, for example hydrates, and the present invention includes each solvate and mixtures thereof.

The present invention also provides pharmaceutical
15 compositions which comprise a compound of formula I as hereinbefore defined together with a pharmaceutically acceptable carrier. Specific compounds which may be incorporated into the compositions of this invention are the novel compounds disclosed above.

20 As used hereinafter, the term "active compound" denotes a quinolone of formula I. In therapeutic use the active compound may be administered orally, rectally, parenterally or topically, preferably orally. Thus the therapeutic compositions of the present
25 invention may take the form of any of the known pharmaceutical compositions for oral, rectal, parenteral or topical administration. The compositions may be formulated in a manner known to those skilled in the art so as to give a controlled release of the
30 compounds of the present invention. Pharmaceutically acceptable carriers suitable for use in such compositions are well known in the art of pharmacy. The compositions of the invention suitably contain 0.1-90% by weight of active compound. The compositions

- 6 -

of the invention are generally prepared in unit dosage form.

5 Compositions for oral administration are the preferred compositions of the invention and these are the known pharmaceutical forms for such administration, for example tablets, capsules, syrups and aqueous or oily suspensions. The excipients used in the preparation of these compositions are the excipients known in the pharmacists' art.

10 Tablets may be prepared by mixing the active compound with an inert diluent, such as lactose or calcium phosphate, in the presence of disintegrating agents, for example maize starch, and lubricating agents, for example magnesium stearate, and tableting
15 the mixture by known methods. Such tablets may if desired be provided with enteric coatings by known methods, for example by the use of cellulose acetate phthalate. Similarly capsules, for example hard or soft gelatin capsules containing the active compound
20 with or without added excipients, may be prepared by conventional means and, if desired, provided with enteric coatings in a known manner. Enteric coated compositions of the invention may be advantageous, depending on the nature of the active compound. The
25 tablets and capsules may conveniently each contain 1-500 mg of the active compound. Other compositions for oral administration include, for example, aqueous suspensions containing the compound of formula I in an aqueous medium in the presence of a non-toxic
30 suspending agent such as sodium carboxymethylcellulose, and oily suspensions containing a compound of the present invention in a suitable vegetable oil, for example arachis oil.

- 7 -

Compositions of the invention suitable for rectal administration are the known pharmaceutical forms for such administration, for example suppositories with semi-synthetic glycerides or polyethylene glycol bases.

- 5 Compositions of the invention suitable for parenteral administration are the known pharmaceutical forms for such administration, for example sterile suspensions in aqueous and oily media or sterile solutions in a suitable solvent.
- 10 Compositions for topical administration may comprise a matrix in which the active compound is dispersed so that it is held in contact with the skin in order to administer the compound of formula I transdermally. Alternatively the active compound may
- 15 be dispersed in a cream or ointment base.

In some formulations it may be beneficial to use the compounds of the present invention in the form of particles of very small size, for example as obtained by fluid energy milling.

- 20 In the compositions of the present invention the active compound may, if desired, be associated with other compatible pharmacologically active ingredients, for example a β -blocker such as propranolol, oxprenolol, atenolol, nadolol or timolol, or a diuretic
- 25 such as bendrofluazide.


- The therapeutic activity of compounds of formula I has been demonstrated by means of tests on standard laboratory animals. Such tests include, for example, the oral administration of the compounds to a strain of
- 30 spontaneously hypertensive rat. Thus, compounds of formula I are useful for reducing blood pressure in hypertensive mammals. Whilst the precise amount of

- 8 -

active compound administered will depend on a number of factors, for example the age of the patient, the severity of the condition and the past medical history and always lies within the sound discretion of the administering physician, a suitable dose for enteral administration to mammals, including humans, is generally within the range 0.01-25 mg/kg/day, more usually 0.2-10 mg/kg/day given in single or divided doses. For parenteral administration, a suitable dose is generally within the range 0.001-2.5 mg/kg/day, more usually 0.005-1 mg/kg/day given in single or divided doses or by continuous infusion. Oral administration is preferred.

Compounds of formula I are vasodilators with an action on both arterial and venous vascular beds. Accordingly, compounds of formula I are indicated for use in the treatment of ischaemic heart disease and heart failure in mammals, including humans. Suitable dosages are as hereinbefore stated.

The compounds of formula I may be prepared by alkylation of a compound of formula III




III

- 9 -

with an alkylating agent of formula $(R^2)_2SO_4$ or an
 alkylating agent of formula R^2Y in which Y is a leaving
 group, for example halo, preferably iodo. The reaction
 may preferably be carried out in the presence of a
 5 base, for example potassium hydroxide.


Compounds of formula I in which m is 0 may be
 prepared by cyclisation of a compound of formula IV



IV

The cyclisation reaction may be effected in the
 presence of an organic or inorganic base or by heating
 the compound of formula IV in a liquid inert to the
 10 conditions of the reaction.

Compounds of formula I in which m is 0 may be
 prepared by reaction of a compound of formula V




V

with a tri(lower alkyl) orthoformate, preferably
 15 trimethyl orthoformate or triethyl orthoformate. The
 reaction may be effected by heating in a solvent inert

- 10 -


to the conditions of the reaction in the presence of a base such as, for example, piperidine.

Compounds of formula I in which n is 0 or 2 and m is 0 may also be prepared by cyclisation of a
5 corresponding acrylate of formula VI



in which R⁷ is lower alkyl, preferably methyl or ethyl, and R⁶ is R². Cyclisation may be effected, for example by heating a compound of formula VI in a mixture of acetic anhydride and concentrated sulphuric acid. It
10 will be apparent to those skilled in the art that the reaction may produce a mixture of isomers. The desired compound of formula I may be separated using methods known in the art.


Compounds of formula I in which R³ is halogenated
15 lower alkoxy, halogenated lower alkylthio or halogenated lower alkylsulphonyl in the 7-position of the quinoline ring may be prepared by reaction of a compound of formula VII



- 11 -

in which Z is fluoro, chloro or bromo, preferably fluoro, with the appropriate halogenated anion in a solvent inert to the conditions of the reaction. For example compounds of formula I in which R³ is 7-(2,2,2-trifluoroethoxy) may be prepared from a compound of formula VII in which Z is fluoro by reaction with sodium 2,2,2-trifluoroethoxide in dioxan.

Compounds of formula I in which R³ is halogenated lower alkoxy or halogenated lower alkylthio in the 7-position of the quinoline ring may also be prepared by reaction of a compound of formula VIII



VIII

in which A is oxygen or sulphur and M⁺ is a cation such as an alkali metal cation, for example sodium, with an appropriate alkylating agent. For example compounds of formula I in which R³ is 7-difluoromethoxy may be prepared from a compound of formula VIII in which A is oxygen and M⁺ is sodium by reaction with chlorodifluoromethane.

Compounds of formula I in which R³ is fluorinated lower alkoxy may also be prepared by reaction of a compound of formula I in which R³ is fluorinated chloroalkoxy with a mild fluorinating agent such as potassium fluoride or silver tetrafluoroborate. For example a compound of formula I in which R³ is trifluoromethoxy may be prepared by reaction of a

- 12 -

compound of formula I in which R^3 is chlorodifluoromethoxy with silver tetrafluoroborate.

Compounds of formula I in which R^3 is fluorinated chloroalkoxy or fluorinated chloroalkylthio in the 7-position of the quinoline ring may be prepared by reaction of a compound of formula VIII in which M^+ is a cation such as an alkali metal cation, for example sodium, with a fluorinated polychloroalkane. For example a compound of formula I in which R^3 is chlorodifluoromethoxy may be prepared by reaction of a compound of formula VIII in which A is oxygen and M^+ is sodium with dichlorodifluoromethane.

Compounds of formula I or formula III in which n is 1 or 2 and R^3 is halogenated alkoxy may be prepared by oxidation of a corresponding compound of formula I or formula III in which n is 0 or 1, using for example, a peroxycarboxylic acid such as 3-chloroperoxybenzoic acid as the oxidising agent.

Compounds of formula I or formula III in which n is 1 and R^3 is halogenated alkylthio may be prepared by oxidation of a corresponding compound of formula I or formula III in which n is 0, using for example, a peroxycarboxylic acid such as 3-chloroperoxybenzoic acid as the oxidising agent.

Compounds of formula I or formula III in which n is 2 and R^3 is halogenated alkylsulphanyl may be prepared by oxidation of a corresponding compound of formula I or formula III in which n is 2 and R^3 is halogenated alkylthio, using for example, a peroxycarboxylic acid such as 3-chloroperoxybenzoic acid as the oxidising agent.

- 13 -


Compounds of formula I or formula III in which n is 1 or 2 and R^3 is halogenated alkylsulphonyl may be prepared by oxidation of a corresponding compound of formula I or formula III in which n is 0 or 1, using
5 for example, a peroxycarboxylic acid such as 3-chloroperoxybenzoic acid as the oxidising agent.

Compounds of formula I or formula III in which n is 2 and R^3 is halogenated alkylsulphonyl may be prepared by oxidation of a corresponding compound of
10 formula I or formula III in which n is 0, 1 or 2 and R^3 is halogenated alkylthio or halogenated alkylsulphinyl, using a strong oxidising agent, for example hydrogen peroxide in acetic acid.

Compounds of formula I in which n is 0 and R^3 is
15 halogenated alkylthio may be prepared by reduction of a corresponding compound of formula I in which n is 0 or 1 and R^3 is halogenated alkylsulphinyl using, for example, triphenylphosphine as the reducing agent.

Compounds of formula III in which n is 0 or 2 and
20 m is 0 may be prepared, for example, by cyclisation of a corresponding compound of formula VI in which R^6 is hydrogen. Cyclisation may be effected, for example by heating a compound of formula VI in a liquid inert to the conditions of the reaction such as diphenyl ether
25 for example within the range 200-280°.

Compounds of formula VI may be prepared by reaction of a compound of formula IX



IX

- 14 -

in which R^6 is hydrogen or lower alkyl, with an acrylate of formula X



in which n is 0 or 2 and M^+ is an alkali metal cation, for example sodium.

5 Compounds of formula VIII may be prepared by nucleophilic substitution of a compound of formula VII for example, by reaction of a compound of formula VII in which Z is fluoro with aqueous sodium hydroxide.

10 Compounds of formula IV, V and VII are novel but may be prepared by methods analogous to those described in UK Patent No. 2047691, UK Patent No. 2085441 and European Patent Application No. 0317149 for the preparation of similar compounds. Some of the compounds of formulae IX and X are known but it will be apparent
15 to those skilled in the art that novel compounds may be prepared in a similar manner to the preparation of the known compounds of said formulae.

20 The preferred group of compounds of formula II may be prepared using appropriate methods disclosed hereinbefore for preparing compounds of formula I.

25 The therapeutic activity of compounds of formula I in Table 1 has been demonstrated by the following test which involves the oral administration of the compounds to a strain of spontaneously hypertensive rat. This test was carried out in the following way:

- 15 -

Test

Female rats, weight range 180-240g, of the Aoki-Okamoto strain of spontaneously hypertensive rat were used. The rats in groups of four were fasted overnight before administration of the test compound. Blood pressure was determined in the following way. The rats were placed in a cabinet kept at 38°C with their tails protruding through holes in the cabinet. After 30 minutes in the cabinet blood pressure was measured using an inflatable cuff placed round the base of the tail and arterial pulsations monitored with a pneumatic pulse transducer. A pressure, greater than the expected blood pressure, was applied to the cuff, and this pressure was slowly reduced. The pressure in the cuff at which arterial pulsations reappeared was taken as the blood pressure. The rats were removed from the cabinet and each group orally dosed with a given dose of the test compound given as a solution or suspension in 0.25% aqueous carboxymethylcellulose. In addition to the pre-dose reading, blood pressure was measured at 1.5 and 5.0 hours after dosing. The degree of blood pressure reduction sufficient to achieve a significance level of $p < 0.01$ compared to controls was 9% after correction for control changes at appropriate time intervals. Thus, compounds were considered to be active in this test if they produced a reduction of blood pressure after correction of 9% or greater than 9%.

Threshold antihypertensive doses of compounds of formula I were determined in the following way. Compounds were tested initially at a particular dose level, for example 90 mg/kg. If the compound was considered sufficiently active (giving a reduction of blood pressure equal to or greater than 16% after

- 16 -

correction) it was retested at a lower dose level, for example 30 mg/kg. By testing at successively lower dose levels, a threshold antihypertensive dose (dose giving a reduction of blood pressure of between 9 and 16% after correction) was determined. Compounds inactive at a particular dose level and giving a reduction of blood pressure equal to or greater than 16% after correction at the next highest dose level were designated as having a threshold antihypertensive dose within the range covered by the two dose levels.

The final products of Examples 1 to 7 were active in this test at a dose level of 90 mg/kg or less and the actual results obtained are shown in Table 1 below.

Table 1

	Final Product of Example	Threshold antihypertensive dose (mg/kg)
15		
	1	3-10
20	2	3
	3	3
	4	3-10
	5	10-30
	6	30-90
25	7	30-90

The invention is illustrated by the following non-limitative Examples in which compositions of mixed solvents are given by volume. Novel compounds were

- 17 -

characterised by one or more of the following: elemental analysis, nuclear magnetic resonance and infra-red spectroscopy. Temperatures are given in degrees Celsius.

- 5 Flash chromatography was performed according to the method of Still et al., J. Org. Chem., 43, 2933-5 (1978).

Example 1

(a) Water (80 ml) was added to a stirred mixture of 3-trifluoromethoxyaniline (10 g) and concentrated hydrochloric acid (5 ml) at ambient temperature. The resultant solution was cooled to 0° and a solution of methyl 3-hydroxy-2-(methylthio)acrylate, sodium salt (80 mole %, 11.5 g) in water (60 ml) added over 20 minutes. The mixture was stirred whilst allowing to warm to ambient temperature and then stirred for 4 hours. The solid was collected by filtration and washed with water (2 x 100 ml) to give methyl 2-methylthio-3-(3-trifluoromethoxyanilino)acrylate, m.p. 58-61°.

(b) Methyl 2-methylthio-3-(3-trifluoromethoxyanilino)acrylate (16.5 g) was added portionwise over 15 minutes to boiling diphenyl ether (300 ml) stirred under nitrogen. After stirring at approximately 260° for 30 minutes, the mixture was allowed to cool to ambient temperature and diethyl ether (600 ml) added with stirring. The solid was collected by filtration and washed with diethyl ether (100 ml) to give 4-hydroxy-3-methylthio-7-trifluoromethoxyquinoline, m.p. 270° (dec.).

(c) Dimethyl sulphate (4.5 ml) was added to a stirred solution of 4-hydroxy-3-methylthio-7-trifluoromethoxyquinoline (7 g) and potassium hydroxide (2.85 g) in tetrahydrofuran (15 ml) and water (55 ml) at ambient temperature and the mixture stirred for 5 hours. The solid was collected by filtration and washed with water (2 x 50 ml) to give 1-methyl-3-methylthio-7-trifluoromethoxy-4-quinolone, m.p. 130°.

Example 2

(a) Water (125 ml) was added to a stirred mixture of 3-trifluoromethylthioaniline (17.8 g) and concentrated hydrochloric acid (8.5 ml) and the mixture stirred at 40° for 5 minutes. The resultant solution was cooled to 0° and a solution of methyl 3-hydroxy-2-(methylthio)acrylate, sodium salt (80 mole %, 19.55 g) in water (100 ml) added over 30 minutes. After stirring at ambient temperature for 3 hours the mixture was kept overnight. The mixture was extracted with dichloromethane (3 x 200 ml) and the combined extracts washed with aqueous hydrochloric acid (5M, 75 ml) then water (200 ml). The extract was dried over magnesium sulphate and the solvent removed by evaporation to give methyl 2-methylthio-3-(3-trifluoromethylthioanilino)-acrylate as an oil.

(b) A solution of methyl 2-methylthio-3-(3-trifluoromethylthioanilino)acrylate (26.8g) in warm (30-40°) diphenyl ether (50 ml) was added dropwise over 15 to 20 minutes to boiling diphenyl ether (100 ml) stirred under nitrogen. After stirring at approximately 260° for 25 minutes the mixture was allowed to cool to ambient temperature and diethyl ether (300 ml) added with stirring. The solid was collected by filtration and washed with diethyl ether (100 ml) to give a mixture of 4-hydroxy-3-methylthio-5-trifluoromethylthioquinoline and 4-hydroxy-3-methylthio-7-trifluoromethylthioquinoline, m.p. 222-224°.

(c) Dimethyl sulphate (5.2 ml) was added to a stirred solution of the isomeric mixture of 5- and 7-trifluoromethylthio-4-hydroxy-3-methylthioquinolines (14.55 g) and potassium hydroxide (3.1 g) in tetrahydrofuran (150 ml) and water (200 ml) at ambient temperature. After stirring for 6 hours the mixture was kept

- 20 -

overnight. The solid was collected by filtration, washed with water (2 x 100 ml) and crystallised from industrial methylated spirit (250 ml) to give a mixture of 1-methyl-3-methylthio-5-trifluoromethylthio-4-quinolone and 1-methyl-3-methylthio-7-trifluoromethylthio-4-quinolone. The mixture was dissolved in dichloromethane and separated by high pressure liquid chromatography on a silica gel column eluted with dichloromethane to give 1-methyl-3-methylthio-7-trifluoromethylthio-4-quinolone, m.p. 168-172°.

Example 3

A solution of 3-chloroperoxybenzoic acid (85% w/w, 2.68 g) in dichloromethane (50 ml) was added dropwise over 30 minutes to a stirred solution of 1-methyl-3-methylthio-7-trifluoromethoxy-4-quinolone (4.5 g), prepared as described in Example 1, in dichloromethane (100 ml) at 0-5°. The mixture was allowed to warm to ambient temperature and stirring continued for 2.5 hours. 3-Chloroperoxybenzoic acid (85% w/w, 0.2 g) in dichloromethane (5 ml) was added and the mixture was stirred for 2 hours, then allowed to stand for 2 days. Further 3-chloroperoxybenzoic acid (85% w/w, 0.11 g) was added and the mixture stirred for 4 hours. The mixture was washed with saturated aqueous sodium bicarbonate (2 x 100 ml) then water (100 ml) and the organic phase dried over magnesium sulphate. The solvent was removed by evaporation and the residue crystallised from ethyl acetate (250 ml) to give 1-methyl-3-methylsulphinyl-7-trifluoromethoxy-4-quinolone, m.p. 200-201°.

Example 4

A solution of 3-chloroperoxybenzoic acid (55% w/w, 0.668 g) in dichloromethane (25 ml) was added

- 21 -

dropwise over 2 hours to a stirred solution of 1-methyl-3-methylthio-7-trifluoromethylthio-4-quinolone (0.65 g), prepared as described in Example 2, in dichloromethane (80 ml) at -20°. The mixture was
5 allowed to warm to ambient temperature, then washed with saturated aqueous sodium bicarbonate (2 x 25 ml) followed by water (35 ml) and the organic phase dried over magnesium sulphate. The solvent was removed by evaporation and the residue purified by flash column
10 chromatography on a silica gel column eluted with dichloromethane:industrial methylated spirit (9:1) to give 1-methyl-3-methylsulphonyl-7-trifluoromethylthio-4-quinolone, m.p. 238-239°.

Example 5

15 A solution of 3-chloroperoxybenzoic acid (85% w/w, 0.4 g) in dichloromethane (5 ml) was added to a stirred solution of 1-methyl-3-methylsulphonyl-7-trifluoromethoxy-4-quinolone (0.63 g), prepared as described in Example 3, in dichloromethane (25 ml) at ambient
20 temperature. The mixture was stirred for 3 hours, then washed with saturated aqueous sodium bicarbonate (15 ml) followed by water (20 ml) and the organic phase dried over magnesium sulphate. The solvent was removed by evaporation and the residue crystallised from
25 industrial methylated spirit (10 ml) to give 1-methyl-3-methylsulphonyl-7-trifluoromethoxy-4-quinolone, m.p. 249-250°.

Example 6

30 a) Chlorodifluoromethane was passed into a stirred solution of 7-hydroxy-1-methyl-3-methylthio-4-quinolone (3.4 g), prepared as described in UK Patent No.2047691, and sodium hydroxide (3.0 g) in a mixture of dioxan (10 ml) and water (8 ml) at 90°. Further

- 22 -

dioxan (5 ml) and water (4 ml) were added. Chlorodifluoromethane was passed into the mixture at 90° for a further 20 minutes. The reaction mixture was cooled to ambient temperature, the solid collected
5 by filtration and washed with water (4 x 10 ml) to give 7-difluoromethoxy-1-methyl-3-methylthio-4-quinolone, m.p. 152-159°.

b) A solution of 3-chloroperoxybenzoic acid (85% w/w, 0.33 g) in chloroform (25 ml) was added dropwise
10 to a stirred solution of 7-difluoromethoxy-1-methyl-3-methylthio-4-quinolone (0.54 g) in chloroform (25 ml) at -5°. The mixture was stirred at -5° for 1 hour, poured into saturated aqueous sodium bicarbonate (200 ml) and the layers separated. The aqueous layer was
15 extracted with chloroform (2 x 100 ml). The original chloroform layer and extracts were combined and dried over magnesium sulphate. The solvent was removed by evaporation and the residue crystallised from ethyl acetate to give 7-difluoromethoxy-1-methyl-3-
20 methylsulphiny-4-quinolone, m.p. 198-200°.

Example 7

Sodium (0.45 g) was added portionwise to a stirred mixture of 2,2,2-trifluoroethanol (3 ml) and dry dioxan (30 ml). 7-Fluoro-1-methyl-3-methylsulphiny-4-
25 quinolone (4.5 g), prepared as described in UK Patent No. 2047691, was added to the resultant solution and the mixture stirred at 95-100° for 24 hours. The reaction mixture was cooled to ambient temperature and the solid was collected by filtration and crystallised
30 from industrial methylated spirit (50 ml) to give 1-methyl-3-methylsulphiny-7-(2,2,2-trifluoroethoxy)-4-quinolone, m.p. 288-291°.

- 23 -

Example 8

In the preparation of capsules, 10 parts by weight of active compound and 240 parts by weight of lactose are de-aggregated and blended. The mixture is filled
5 into hard gelatin capsules, each capsule containing 10 mg of active compound.

Example 9

Tablets are prepared from the following ingredients.

10		<u>Parts by weight</u>
	Active compound	10
	Lactose	190
	Maize starch	22
	Polyvinylpyrrolidone	10
15	Magnesium stearate	3

The active compound, the lactose and some of the starch are de-aggregated, blended and the resulting mixture is granulated with a solution of the polyvinylpyrrolidone in ethanol. The dry granulate is
20 blended with the magnesium stearate and the rest of the starch. The mixture is then compressed in a tableting machine to give tablets containing 10 mg of active compound.

Example 10

25 Tablets are prepared by the method of Example 9. The tablets are enteric coated in a conventional manner using a solution of 20% cellulose acetate phthalate and 3% diethyl phthalate in ethanol:dichloromethane (1:1).

Example 11

In the preparation of suppositories, 100 parts by weight of active compound is incorporated in 1300 parts by weight of semi-synthetic glycerides as the
5 suppository base and the mixture formed into suppositories each containing 100 mg of active ingredient.


Example 12

In the preparation of capsules, 50 parts by weight
10 of active compound, 300 parts by weight of lactose and 3 parts by weight of magnesium stearate are de-aggregated and blended. The mixture is filled into hard gelatin capsules, each capsule containing 50 mg of active compound.

- 25 -


Claims

1. A compound of formula I



in which R^1 is lower alkyl; R^2 is lower alkyl; R^3 is
 5 halogenated lower alkoxy, halogenated lower alkylthio,
 halogenated lower alkylsulphinyl or halogenated lower
 alkylsulphonyl; R^4 and R^5 , which may be the same or
 different, are hydrogen, lower alkyl, lower alkoxy,
 lower alkylthio, lower alkylsulphinyl, lower
 alkylsulphonyl, halo, halogenated lower alkyl,
 10 halogenated lower alkoxy, halogenated lower alkylthio,
 halogenated lower alkylsulphinyl, halogenated lower
 alkylsulphonyl, cyano, phenyl or phenyl substituted by
 1 to 3, especially 1 or 2, groups selected from lower
 alkyl, lower alkoxy, halo or halogenated lower alkyl; m
 15 is 0 or 1; and n is 0, 1 or 2.

2. A compound as claimed in claim 1 represented by
 formula II



in which R^1 is lower alkyl; R^2 is lower alkyl; R^3 is
 halogenated lower alkoxy, halogenated lower alkylthio,


- 26 -

halogenated lower alkylsulphanyl or halogenated lower alkylsulphonyl; and n is 0, 1 or 2.

3. A compound as claimed in claim 2 in which R¹ is alkyl having 1 to 4 carbon atoms; R² is alkyl having 1 to 4 carbon atoms; R³ is fluorinated alkoxy having 1 to 4 carbon atoms, fluorinated alkylthio having 1 to 4 carbon atoms, fluorinated alkylsulphanyl having 1 to 4 carbon atoms or fluorinated alkylsulphonyl having 1 to 4 carbon atoms; and n is 0, 1 or 2.
- 10 4. A compound as claimed in claim 3 in which R³ is trifluoromethoxy, 2,2,2-trifluoroethoxy, difluoromethoxy or trifluoromethylthio.
5. A compound as claimed in claim 4 in which R¹ and R² are methyl.
- 15 6. 1-Methyl-3-methylthio-7-trifluoromethoxy-4-quinolone.
7. A pharmaceutical composition which comprises a compound of formula I as claimed in any one of claims 1 to 6 together with a pharmaceutically acceptable carrier.
- 20 8. A method of treating hypertension in a mammal in need of such treatment which comprises the administration of a compound of formula I as claimed in any one of claims 1 to 6.
- 25 9. A compound of formula I as claimed in any one of claims 1 to 6 for the manufacture of a medicament for the treatment of hypertension.
10. A process for the preparation of compounds of formula I as claimed in claim 1 which comprises

- 27 -


(a) alkylation of a compound of formula III



III

with an alkylating agent of formula $(R^2)_2SO_4$ or an alkylating agent of formula R^2Y in which Y is a leaving group;


- 5 (b) to prepare compounds of formula I in which R^3 is halogenated lower alkoxy, halogenated lower alkylthio or halogenated lower alkylsulphonyl in the 7-position of the quinoline ring, reaction of a compound of formula VII



VII

- 10 in which Z is fluoro, chloro or bromo, with the appropriate halogenated anion in a solvent inert to the conditions of the reaction; or

- (c) to prepare compounds of formula I in which R^3 is halogenated lower alkoxy or halogenated lower alkylthio
 15 in the 7-position of the quinoline ring, reaction of a compound of formula VIII



VIII

in which A is oxygen or sulphur and M^+ is a cation, with an appropriate alkylating agent.

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO.

EP 9001376
SA 39413

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 03/12/90. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB-A- 2085441	28-04-82	AU-B- 549078	16-01-86
		AU-A- 7552481	01-04-82
		CA-A- 1146943	24-05-83
		CH-A- 650254	15-07-85
		DE-A- 3138121	15-04-82
		FR-A, B 2491064	02-04-82
		LU-A- 83649	22-02-83
		NL-A- 8104394	16-04-82
		SE-B- 457533	09-01-89
		SE-A- 8105689	27-03-82
		SU-A- 1287745	30-01-87
		US-A- 4442109	10-04-84
		US-A- 4447435	08-05-84
FR-A- 2452484	24-10-80	AU-B- 536616	17-05-84
		AU-A- 5670280	02-10-80
		BE-A- 882443	26-09-80
		CA-A- 1151652	09-08-83
		CA-A- 1171789	31-07-84
		CH-A- 644366	31-07-84
		DE-A- 3011994	16-10-80
		DE-A- 3051205	15-02-90
		FR-A, B 2468367	08-05-81
		GB-A, B 2047691	03-12-80
		GB-A, B 2111975	13-07-83
		JP-A, B, C55130960	11-10-80
		JP-A- 62215526	22-09-87
		LU-A- 82295	17-04-81
		NL-A- 8001771	30-09-80
		SE-B- 455422	11-07-88
		SE-A- 8002345	28-09-80
		US-A- 4302460	24-11-81
EP-A- 0206616	30-12-86	AU-A- 5838286	18-12-86
		JP-A- 62036361	17-02-87
		US-A- 4772614	20-09-88

EPO FORM 10079

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82